title: Effects of one-week versus one-day preoperative treatment with topical 1% prednisolone acetate in dogs undergoing phacoemulsification.
abstract: OBJECTIVE
  To compare the effects of 2 preoperative anti-inflammatory regimens on intraocular inflammation following phacoemulsification.
  
  
  METHODS
  Randomized controlled trial
  
  
  METHODS
  21 dogs with immature cataracts.
  
  
  METHODS
  All dogs had cataract surgery via phacoemulsification, and most received prosthetic intraocular lenses. Dogs were randomly divided into 2 groups. Group A dogs were treated topically with prednisolone acetate for 7 days prior to surgery, whereas prednisolone acetate treatment commenced the evening prior to surgery in group B dogs. Postoperative care was identical for both groups. Blood-aqueous barrier breakdown was quantified by use of anterior chamber fluorophotometry, with fluorescein entry into the anterior chamber measured 2 and 9 days after surgery compared with baseline scans obtained prior to surgery. Ophthalmic examinations were performed before surgery and 1 day, 9 days, 3 weeks, 7 weeks, 3 months, and 6 months after surgery. A subjective inflammation score was established at each examination. Intraocular pressures were measured 4 and 8 hours after surgery and at each follow-up examination.
  
  
  RESULTS
  There was no difference in the extent of blood-aqueous barrier disruption between the groups at 2 or 9 days after surgery. Subjective inflammation scores were also similar at most time points. Dogs in group A developed postoperative ocular hypertension at a higher frequency (60%) than did those in group B (18%).
  
  
  CONCLUSIONS
  In dogs that underwent cataract surgery via phacoemulsification, a full week of topical prednisolone acetate treatment prior to surgery did not decrease postoperative inflammation, compared with commencement of topical prednisolone acetate treatment the evening prior to surgery, and was associated with a greater incidence of postoperative ocular hypertension.
authors.affiliation: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: McLean
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Ward
authors.forename: Diane V H
authors.initials: DV
authors.lastname: Hendrix
authors.forename: Rachel K
authors.initials: RK
authors.lastname: Vaughn
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002386:Cataract / Q000628:therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D008297:Male; D009798:Ocular Hypertension / Q000139:chemically induced / Q000662:veterinary; D018918:Phacoemulsification / Q000662:veterinary*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; C009935:prednisolone acetate; D011239:Prednisolone